Biomarkers blood, urine and microbiota samples
Pre-clinicalActive 2 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Dec 24, 2018 → Dec 30, 2036
NCT ID
NCT03958136About Biomarkers blood, urine and microbiota samples
Biomarkers blood, urine and microbiota samples is a pre-clinical stage product being developed by Eli Lilly for Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03958136. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
3
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03958136 | Pre-clinical | Active |
Competing Products
20 competing products in Breast Cancer